These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25574915)

  • 81. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
    Peresu E; De Graeve D; Heunis JC; Kigozi NG
    PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Multidrug-resistant tuberculosis.
    Dheda K; Mirzayev F; Cirillo DM; Udwadia Z; Dooley KE; Chang KC; Omar SV; Reuter A; Perumal T; Horsburgh CR; Murray M; Lange C
    Nat Rev Dis Primers; 2024 Mar; 10(1):22. PubMed ID: 38523140
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses.
    Pepper DJ; Rebe K; Morroni C; Wilkinson RJ; Meintjes G
    PLoS One; 2009; 4(2):e4520. PubMed ID: 19229341
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
    Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
    BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Examining the cost of community-based tuberculosis treatment in South Africa.
    Moran A; Kula N; Jagwer G; Broughton E; Pillay Y; Mvusi L; AlMossawi H; Ndjeka N; Mametja D; Dlamini C; Ahmedov S; Matji R; Kak N
    Int J Tuberc Lung Dis; 2020 Jun; 24(6):612-618. PubMed ID: 32552992
    [No Abstract]   [Full Text] [Related]  

  • 87. Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.
    Campbell JR; Falzon D; Mirzayev F; Jaramillo E; Migliori GB; Mitnick CD; Ndjeka N; Menzies D
    Emerg Infect Dis; 2020 Mar; 26(3):. PubMed ID: 31922953
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
    McNaughton A; Blackmore T; McNaughton H
    Eur Respir J; 2016 Oct; 48(4):1256-1259. PubMed ID: 27694421
    [No Abstract]   [Full Text] [Related]  

  • 89. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
    Tsang CA; Shah N; Armstrong LR; Marks SM
    Clin Infect Dis; 2020 Feb; 70(5):907-916. PubMed ID: 30944927
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022].
    Yu JJ; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jan; 46(1):62-66. PubMed ID: 36617931
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa.
    Mokhele I; Jinga N; Berhanu R; Dlamini T; Long L; Evans D
    BMC Pregnancy Childbirth; 2021 Jun; 21(1):453. PubMed ID: 34182944
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cost-effectiveness of treating multidrug- and extensively drug-resistant tuberculosis: A systematic review.
    Vo NX; Thuy Nguyen TT; Phuong Thao NT; Thanh Ho HP; Vo TQ
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S131-S136. PubMed ID: 31369543
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 97. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers.
    O'Donnell MR; Jarand J; Loveday M; Padayatchi N; Zelnick J; Werner L; Naidoo K; Master I; Osburn G; Kvasnovsky C; Shean K; Pai M; Van der Walt M; Horsburgh CR; Dheda K
    Ann Intern Med; 2010 Oct; 153(8):516-22. PubMed ID: 20956708
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Multidrug-resistant tuberculosis around the world: what progress has been made?
    Falzon D; Mirzayev F; Wares F; Baena IG; Zignol M; Linh N; Weyer K; Jaramillo E; Floyd K; Raviglione M
    Eur Respir J; 2015 Jan; 45(1):150-60. PubMed ID: 25261327
    [TBL] [Abstract][Full Text] [Related]  

  • 99. High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission.
    Bantubani N; Kabera G; Connolly C; Rustomjee R; Reddy T; Cohen T; Pym AS
    PLoS One; 2014; 9(3):e90868. PubMed ID: 24625669
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.